(Q52950284)

9 May 2018

title

Atypical depression spectrum disorder - neurobiology and treatment. (English)

1 reference

9 May 2018

1 reference

Harald Murck

1

1 reference

9 May 2018

publication date

1 August 2003

1 reference

9 May 2018

published in

Acta Neuropsychiatrica

1 reference

9 May 2018

volume

15

1 reference

9 May 2018

issue

4

1 reference

9 May 2018

page(s)

227-241

1 reference

9 May 2018

Psychiatric disorders in patients with fibromyalgia. A multicenter investigation.

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Chronic fatigue syndrome and seasonal affective disorder: comorbidity, diagnostic overlap, and implications for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Screening for psychiatric disorders in chronic fatigue and chronic fatigue syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Moclobemide and fluoxetine in atypical depression: a double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Functional somatic syndromes: one or many?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The validity of major depression with atypical features based on a community study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Glucocorticoid receptors, fibromyalgia and low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Neurovegetative symptoms in chronic pain and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Decreased pituitary sensitivity to glucocorticoids in endurance-trained men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cerebrospinal Fluid Immunoreactive Cortieotropin-Releasing Hormone and Adrenocorticotropin Secretion in Cushing's Disease and Major Depression: Potential Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Gender differences in treatment response to sertraline versus imipramine in chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Toward validation of atypical depression in the community: results of the Zurich cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Psychiatric illness in patients with persistent somatisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

St Johns wort increases expression of P-glycoprotein: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Depressive Classification and Prediction of Response to Phenelzine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Role for serotonin3 receptors in the control of adrenocorticotropic hormone release from rat pituitary cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Response to phenelzine and amitriptyline in subtypes of outpatient depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Pharmacotherapy response and diagnostic validity in atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Neuraesthenia revisited: ICD-10 and DSM-III-R psychiatric syndromes in chronic fatigue patients and comparison subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Psychiatric disorders and medical care utilization among people in the general population who report fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Burnout, perceived stress, and cortisol responses to awakening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Elevated levels of psychophysiological arousal and cortisol in patients with somatization syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Neurohormonal perturbations in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Corticotropin-releasing factor, norepinephrine, and stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Inhibition of the cortisol response to surgical stress in chronically depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Hormonal evidence for altered responsiveness to social stress in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Disturbed glucocorticoid receptor autoregulation and corticotropin response to dexamethasone in depressives pretreated with metyrapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Adrenal gland enlargement in major depression. A computed tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Urinary free cortisol in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Contrasting neuroendocrine responses in depression and chronic fatigue syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cortisol, thyroid hormone, and mood in atypical depression: a longitudinal case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cortisol measures in primary major depressive disorder with hypersomnia or appetite increase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Does the dexamethasone suppression test relate to subtypes, factors, symptoms, or severity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Symptom profiles of biological markers in depression: a multivariate study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Weight loss, cortisol levels, and dexamethasone suppression in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Urinary free cortisol excretion in elderly persons with minor and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Clinical, endocrine and neurochemical effects of moclobemide in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Red blood cell magnesium and chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A double-blind placebo controlled trial of fluoxetine in fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Hypericum treatment of mild depressions with somatic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Comparison of St John's wort and imipramine for treating depression: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Hypericum for fatigue - a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Hypericum in seasonal affective disorder (SAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Sleep EEG and DST findings in anergic bipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cognitive Performance Test: A New Approach to Functional Assessment in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Treatment of Seasonal Affective Disorder (SAD) with Hypericum Extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Nosology of atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Psychopathology in patients with endogenous Cushing's syndrome: ‘atypical’ or melancholic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Lifetime diagnoses in patients with somatoform disorders: which came first?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Bupropion slow-release response in depression: diagnosis and biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Fluoxetine versus phenelzine in atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Somatic Symptom Index (SSI): A New and Abridged Somatization Construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Neurasthenia in a longitudinal cohort study of young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Clinical validity of ICD-10 neurasthenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Adrenocortical activity and some clinical findings in acute and chronic fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Circadian temperature and cortisol rhythms during a constant routine are phase-delayed in hypersomnic winter depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Factors interfering with the 1 mg dexamethasone suppression test in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Cerebrospinal fluid and plasma free cortisol concentrations in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Fluvoxamine for somatoform disorders: an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

A randomized controlled trial of citalopram in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Moclobemide (Aurorix) in primary major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981-1994.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-5215.2003.00029.X

7 January 2021

10.1034/J.1601-5215.2003.00029.X

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

26983570

1 reference

9 May 2018